IRulya Therapeutics Inc. (IRLA) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 14 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Fri, Nov 13, 2026after close 44 8-K
Q2 FY2026Fri, Aug 14, 2026before open 45 8-K
Q4 FY2025Thu, Feb 12, 2026before open 43 8-K
Q3 FY2025Wed, Nov 12, 2025after close 43 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Tue, May 13, 2025before open 43 8-K
Q4 FY2024Mon, Mar 24, 2025after close 83 8-K
Q3 FY2024Wed, Nov 13, 2024after close 44 8-K

What they guided beta

Q3 FY2026 "Exhibit 99.1 IRulya Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results Name changed from Quince Therapeutics, Inc. to IRulya Therapeutics Inc.; common stock began trading on the Nasdaq Capital Market under the ticker “IRLA” on October 12, 2026 Phase 2 data in bronchiolitis obliterans syndrome (BOS) post lung transplant anticipated in the first quarter of 2027 Cash, cash equivalents and investments of $105.2 million as of September 30, 2026 expected to fund operations through the end of 2028 with multiple Phase 2 clinical data readouts NEW HAVEN, Conn.," exhibit
Q3 FY2026 "The Company expects that its cash position will be sufficient to fund operations through the end of 2028." exhibit
Q2 FY2026 "Exhibit 99.1 Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027 Closed private placement financing, receiving $115 million in upfront gross proceeds, with potential for up to an additional $83 million upon exercise of warrants (including warran" exhibit
Q2 FY2026 "The company also continues to expect data from the Phase 2 trial of LAM-001 in BOS in the first quarter of 2027." exhibit
Q2 FY2026 "The Phase 2 trial of LAM-001 in SAPH is anticipated to begin in late 2026, with data expected in the fourth quarter of 2028." exhibit
Q2 FY2026 "The Company expects that its cash position will be sufficient to fund operations through the end of 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IRLA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IRLA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

IRLA earnings date badge

HTML

<a href="https://veritasdata.dev/company/IRLA/"><img src="https://veritasdata.dev/embed/IRLA.svg" alt="IRLA earnings date" width="240" height="56"></a>

Markdown

[![IRLA earnings date](https://veritasdata.dev/embed/IRLA.svg)](https://veritasdata.dev/company/IRLA/)

Script

<script async src="https://veritasdata.dev/embed/IRLA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IRLA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.